Mobile App

Google Play Apple Store
From Recognition to Lifelong Management in NF1-PN
AMA/ABS/ANCC- Mini Modules
Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Through clinical case scenarios and practical learning activities, participants will strengthen their understanding of NF1-PN pathophysiology, the rationale for MEK pathway targeting, and the clinical features that should prompt further evaluation or referral.

Designed for front-line clinicians, these foundational modules provide the knowledge and confidence to recognize NF1-PN, understand emerging treatment approaches, and navigate early management decisions in a rapidly evolving therapeutic landscape.
Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri

From Recognition to Lifelong Management in NF1-PN
AMA/ABS/ANCC- Mini Modules

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri

Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Through clinical case scenarios and practical learning activities, participants will strengthen their understanding of NF1-PN pathophysiology, the rationale for MEK pathway targeting, and the clinical features that should prompt further evaluation or referral.

Designed for front-line clinicians, these foundational modules provide the knowledge and confidence to recognize NF1-PN, understand emerging treatment approaches, and navigate early management decisions in a rapidly evolving therapeutic landscape.
Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri


 

Thank you for completing this activity!


An email will be sent to you shortly with your certificate attached. If you do not receive this email within 30 minutes, please check your "Junk" or "Spam" folder. You can also visit your profile page for a list of downloadable certificates you've earned.

For your convenience you can download your certificate by clicking the button below.


If you have any questions or experience issues, please contact us.


Overview

Build a practical foundation for recognizing and managing NF1-PN. These evidence-based mini-modules explores the biology and clinical presentation of NF1-PN, with a focus on early recognition, clinical decision-making, and appropriate next steps in care.

Through clinical case scenarios and practical learning activities, participants will strengthen their understanding of NF1-PN pathophysiology, the rationale for MEK pathway targeting, and the clinical features that should prompt further evaluation or referral.

Designed for front-line clinicians, these foundational modules provide the knowledge and confidence to recognize NF1-PN, understand emerging treatment approaches, and navigate early management decisions in a rapidly evolving therapeutic landscape.

From Recognition to Lifelong Management in NF1-PN

AMA/ABS/ANCC- Mini Modules
3 episodes | 1 credit hour

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, Missouri


20
Supported by an independent educational grant from Alexion, AstraZeneca Rare Disease

Launch/Release Date: October 6, 2026
Activity Expiration Date: September 30, 2027

Multipage
8154
NF1(700 x 250 px) (3).png
False
  • Neurology
Neurology
Change Settings